Hugel reported record H1 2026 results, with botulinum toxin sales driving growth across global aesthetics and cosmetics divisions. The Seoul-based company's international footprint expansion—particularly in emerging markets where regulatory pathways are opening—has offset mature-market saturation and generic pressure.
Hugel's toxin portfolio includes BOTULAX and NEURONOX, both competing in price-sensitive geographies where AbbVie and Evolus have limited penetration. The record H1 reflects both volume growth and favorable FX, but also signals that toxin commoditization is advancing fastest in developed markets, pushing manufacturers to pursue emerging-market share and adjacent indications.